Vanguard Group Inc. Has $307.20 Million Position in Palomar Holdings, Inc. $PLMR

Vanguard Group Inc. raised its position in Palomar Holdings, Inc. (NASDAQ:PLMR) by 3.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,631,240 shares of the company’s stock after acquiring an additional 77,515 shares during the period. Vanguard Group Inc. owned about 9.82% of Palomar worth $307,197,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Allworth Financial LP lifted its holdings in shares of Palomar by 1,970.0% during the 2nd quarter. Allworth Financial LP now owns 207 shares of the company’s stock worth $32,000 after acquiring an additional 197 shares during the period. Salomon & Ludwin LLC acquired a new stake in Palomar during the third quarter valued at approximately $25,000. Richardson Financial Services Inc. grew its stake in shares of Palomar by 210.0% in the 3rd quarter. Richardson Financial Services Inc. now owns 217 shares of the company’s stock valued at $25,000 after purchasing an additional 147 shares during the period. Hollencrest Capital Management raised its holdings in shares of Palomar by 56.5% in the 2nd quarter. Hollencrest Capital Management now owns 313 shares of the company’s stock worth $48,000 after buying an additional 113 shares in the last quarter. Finally, NewEdge Advisors LLC bought a new position in shares of Palomar during the 1st quarter worth approximately $66,000. 90.25% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on PLMR shares. JPMorgan Chase & Co. boosted their price target on shares of Palomar from $155.00 to $160.00 and gave the company an “overweight” rating in a research report on Monday, February 23rd. Evercore initiated coverage on Palomar in a research report on Monday, February 9th. They issued an “outperform” rating and a $150.00 price objective for the company. Weiss Ratings upgraded Palomar from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, January 14th. Wall Street Zen raised shares of Palomar from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Keefe, Bruyette & Woods upped their target price on shares of Palomar from $170.00 to $171.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 6th. Seven research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Palomar presently has a consensus rating of “Buy” and a consensus target price of $163.00.

Insiders Place Their Bets

In other news, insider Jonathan Knutzen sold 281 shares of the business’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $128.04, for a total value of $35,979.24. Following the completion of the transaction, the insider owned 27,579 shares of the company’s stock, valued at $3,531,215.16. The trade was a 1.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Mac Armstrong sold 5,000 shares of Palomar stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $122.60, for a total value of $613,000.00. Following the transaction, the chief executive officer owned 343,388 shares in the company, valued at approximately $42,099,368.80. This represents a 1.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 58,999 shares of company stock worth $7,253,229 over the last ninety days. Company insiders own 3.70% of the company’s stock.

Palomar Price Performance

Shares of NASDAQ PLMR opened at $123.71 on Friday. Palomar Holdings, Inc. has a fifty-two week low of $107.75 and a fifty-two week high of $175.85. The firm has a market capitalization of $3.30 billion, a P/E ratio of 17.23 and a beta of 0.44. The company’s 50 day simple moving average is $128.55 and its 200 day simple moving average is $123.20.

Palomar (NASDAQ:PLMR) last posted its quarterly earnings results on Wednesday, February 11th. The company reported $2.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.06 by $0.18. Palomar had a return on equity of 22.77% and a net margin of 22.50%.The business had revenue of $253.36 million for the quarter, compared to analyst estimates of $204.58 million. During the same period last year, the company earned $1.52 EPS. The firm’s revenue was up 62.7% on a year-over-year basis. Sell-side analysts expect that Palomar Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Key Palomar News

Here are the key news stories impacting Palomar this week:

• Positive Sentiment: Zacks Research raised FY2026 EPS to $9.00 (from $8.00) and boosted FY2027 to $9.60 and FY2028 to $12.60 — a sizeable multi‑year upgrade that implies stronger forward profitability. MarketBeat PLMR
• Positive Sentiment: Zacks lifted several near‑term quarterly estimates: Q1 2026 to $2.07 (from $1.89), Q2 2026 to $1.95 (from $1.87), and Q3 2026 to $2.67 (from $1.91). They also raised Q1–Q3 2027 quarterlies (Q1 2027 to $2.46, Q2 2027 to $2.30, Q3 2027 to $2.82), reflecting a consistent upward revision pattern. MarketBeat PLMR
• Neutral Sentiment: A Zacks feature summarizing Street views notes the average analyst price target implies roughly 36.2% upside for PLMR — a bullish signal for sentiment but not a guarantee of price moves. Wall Street Analysts Think Palomar Could Surge
• Negative Sentiment: Zacks trimmed its Q4 2026 estimate slightly to $2.30 from $2.34 — a modest downgrade that appears isolated versus broad upward revisions elsewhere. MarketBeat PLMR

About Palomar

Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.